Cargando…
SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey
INTRODUCTION: As of 26 March 2021, the Africa Centres for Disease Control and Prevention had reported 4 159 055 cases of COVID-19 and 111 357 deaths among the 55 African Union member states; however, no country has published a nationally representative serosurvey as of October 2021. Such data are vi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587532/ https://www.ncbi.nlm.nih.gov/pubmed/34764148 http://dx.doi.org/10.1136/bmjgh-2021-007271 |
_version_ | 1784598171010203648 |
---|---|
author | Barrie, Mohamed Bailor Lakoh, Sulaiman Kelly, J Daniel Kanu, Joseph Sam Squire, James Sylvester Koroma, Zikan Bah, Silleh Sankoh, Osman Brima, Abdulai Ansumana, Rashid Goldberg, Sarah A Chitre, Smit Osuagwu, Chidinma Frankfurter, Raphael Maeda, Justin Barekye, Bernard Numbere, Tamuno-Wari Abdulaziz, Mohammed Mounts, Anthony Blanton, Curtis Singh, Tushar Samai, Mohamed Vandi, Mohamed Richardson, Eugene T |
author_facet | Barrie, Mohamed Bailor Lakoh, Sulaiman Kelly, J Daniel Kanu, Joseph Sam Squire, James Sylvester Koroma, Zikan Bah, Silleh Sankoh, Osman Brima, Abdulai Ansumana, Rashid Goldberg, Sarah A Chitre, Smit Osuagwu, Chidinma Frankfurter, Raphael Maeda, Justin Barekye, Bernard Numbere, Tamuno-Wari Abdulaziz, Mohammed Mounts, Anthony Blanton, Curtis Singh, Tushar Samai, Mohamed Vandi, Mohamed Richardson, Eugene T |
author_sort | Barrie, Mohamed Bailor |
collection | PubMed |
description | INTRODUCTION: As of 26 March 2021, the Africa Centres for Disease Control and Prevention had reported 4 159 055 cases of COVID-19 and 111 357 deaths among the 55 African Union member states; however, no country has published a nationally representative serosurvey as of October 2021. Such data are vital for understanding the pandemic’s progression on the continent, evaluating containment measures, and policy planning. METHODS: We conducted a cross-sectional, nationally representative, age-stratified serosurvey in Sierra Leone in March 2021 by randomly selecting 120 Enumeration Areas throughout the country and 10 randomly selected households in each of these. One to two persons per selected household were interviewed to collect information on sociodemographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. Capillary blood was collected by fingerstick, and blood samples were tested using the Hangzhou Biotest Biotech RightSign COVID-19 IgG/IgM Rapid Test Cassette. Total seroprevalence was estimated after applying sampling weights. RESULTS: The overall weighted seroprevalence was 2.6% (95% CI 1.9% to 3.4%). This was 43 times higher than the reported number of cases. Rural seropositivity was 1.8% (95% CI 1.0% to 2.5%), and urban seropositivity was 4.2% (95% CI 2.6% to 5.7%). DISCUSSION: Overall seroprevalence was low compared with countries in Europe and the Americas (suggesting relatively successful containment in Sierra Leone). This has ramifications for the country’s third wave (which started in June 2021), during which the average number of daily reported cases was 87 by the end of the month:this could potentially be on the order of 3700 actual infections per day, calling for stronger containment measures in a country with only 0.2% of people fully vaccinated. It may also reflect significant under-reporting of incidence and mortality across the continent. |
format | Online Article Text |
id | pubmed-8587532 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-85875322021-11-15 SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey Barrie, Mohamed Bailor Lakoh, Sulaiman Kelly, J Daniel Kanu, Joseph Sam Squire, James Sylvester Koroma, Zikan Bah, Silleh Sankoh, Osman Brima, Abdulai Ansumana, Rashid Goldberg, Sarah A Chitre, Smit Osuagwu, Chidinma Frankfurter, Raphael Maeda, Justin Barekye, Bernard Numbere, Tamuno-Wari Abdulaziz, Mohammed Mounts, Anthony Blanton, Curtis Singh, Tushar Samai, Mohamed Vandi, Mohamed Richardson, Eugene T BMJ Glob Health Original Research INTRODUCTION: As of 26 March 2021, the Africa Centres for Disease Control and Prevention had reported 4 159 055 cases of COVID-19 and 111 357 deaths among the 55 African Union member states; however, no country has published a nationally representative serosurvey as of October 2021. Such data are vital for understanding the pandemic’s progression on the continent, evaluating containment measures, and policy planning. METHODS: We conducted a cross-sectional, nationally representative, age-stratified serosurvey in Sierra Leone in March 2021 by randomly selecting 120 Enumeration Areas throughout the country and 10 randomly selected households in each of these. One to two persons per selected household were interviewed to collect information on sociodemographics, symptoms suggestive of COVID-19, exposure history to laboratory-confirmed COVID-19 cases, and history of COVID-19 illness. Capillary blood was collected by fingerstick, and blood samples were tested using the Hangzhou Biotest Biotech RightSign COVID-19 IgG/IgM Rapid Test Cassette. Total seroprevalence was estimated after applying sampling weights. RESULTS: The overall weighted seroprevalence was 2.6% (95% CI 1.9% to 3.4%). This was 43 times higher than the reported number of cases. Rural seropositivity was 1.8% (95% CI 1.0% to 2.5%), and urban seropositivity was 4.2% (95% CI 2.6% to 5.7%). DISCUSSION: Overall seroprevalence was low compared with countries in Europe and the Americas (suggesting relatively successful containment in Sierra Leone). This has ramifications for the country’s third wave (which started in June 2021), during which the average number of daily reported cases was 87 by the end of the month:this could potentially be on the order of 3700 actual infections per day, calling for stronger containment measures in a country with only 0.2% of people fully vaccinated. It may also reflect significant under-reporting of incidence and mortality across the continent. BMJ Publishing Group 2021-11-11 /pmc/articles/PMC8587532/ /pubmed/34764148 http://dx.doi.org/10.1136/bmjgh-2021-007271 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Barrie, Mohamed Bailor Lakoh, Sulaiman Kelly, J Daniel Kanu, Joseph Sam Squire, James Sylvester Koroma, Zikan Bah, Silleh Sankoh, Osman Brima, Abdulai Ansumana, Rashid Goldberg, Sarah A Chitre, Smit Osuagwu, Chidinma Frankfurter, Raphael Maeda, Justin Barekye, Bernard Numbere, Tamuno-Wari Abdulaziz, Mohammed Mounts, Anthony Blanton, Curtis Singh, Tushar Samai, Mohamed Vandi, Mohamed Richardson, Eugene T SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey |
title | SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey |
title_full | SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey |
title_fullStr | SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey |
title_full_unstemmed | SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey |
title_short | SARS-CoV-2 antibody prevalence in Sierra Leone, March 2021: a cross-sectional, nationally representative, age-stratified serosurvey |
title_sort | sars-cov-2 antibody prevalence in sierra leone, march 2021: a cross-sectional, nationally representative, age-stratified serosurvey |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587532/ https://www.ncbi.nlm.nih.gov/pubmed/34764148 http://dx.doi.org/10.1136/bmjgh-2021-007271 |
work_keys_str_mv | AT barriemohamedbailor sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT lakohsulaiman sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT kellyjdaniel sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT kanujosephsam sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT squirejamessylvester sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT koromazikan sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT bahsilleh sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT sankohosman sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT brimaabdulai sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT ansumanarashid sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT goldbergsaraha sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT chitresmit sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT osuagwuchidinma sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT frankfurterraphael sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT maedajustin sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT barekyebernard sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT numberetamunowari sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT abdulazizmohammed sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT mountsanthony sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT blantoncurtis sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT singhtushar sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT samaimohamed sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT vandimohamed sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey AT richardsoneugenet sarscov2antibodyprevalenceinsierraleonemarch2021acrosssectionalnationallyrepresentativeagestratifiedserosurvey |